Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 816 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Butyrate Clear all
Completed Phase 2Phase 3 Interventional Results available

Prometa Protocol for Alcohol Dependence

NCT00262639
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Flumazenil and Gabapentin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 23, 2026, 3:38 PM EDT
Recruiting Not applicable Interventional

Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19

NCT04858412
View directory record Official record
Conditions
Alcoholic Liver Disease, COVID 19 Pneumonia
Interventions
β-hydroxy β-methyl butyrate (HMB) enriched amino acid, Balanced amino acid
Dietary Supplement
Lead sponsor
The Cleveland Clinic
Other
Eligibility
21 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 3:38 PM EDT
Completed Phase 2 Interventional Results available

Vigabatrin and Insulin Sensitivity

NCT04321395
View directory record Official record
Conditions
NAFLD, Obesity
Interventions
Vigabatrin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 23, 2026, 3:38 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

NCT07634471
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
MK-1045, Rituximab, Rituximab biosimilar, Bendamustine, Cyclophosphamide, Vincristine, Prednisone, Prednisolone, Doxorubicin Hydrochloride
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
5
States / cities
Duarte, California • Lexington, Kentucky • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 3:38 PM EDT
Terminated Phase 3 Interventional Results available

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

NCT02951156
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Avelumab, Utomilumab, Rituximab, Azacitidine, Bendamustine, Gemcitabine, Oxaliplatin
Biological · Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Duarte, California • Louisville, Kentucky • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 23, 2026, 3:38 PM EDT
Active, not recruiting Phase 1 Interventional

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

NCT01479842
View directory record Official record
Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions
BTK inhibitor PCI-32765, rituximab, bendamustine hydrochloride, pharmacogenomic studies, pharmacological study, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
Kami Maddocks, MD
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 23, 2026, 3:38 PM EDT
Completed Phase 3 Interventional Results available

Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.

NCT00777023
View directory record Official record
Conditions
Hot Flashes
Interventions
Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg, Placebo
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
45
States / cities
Birmingham, Alabama • Chandler, Arizona • Scottsdale, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 23, 2026, 3:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Non-fasting Conditions

NCT00865059
View directory record Official record
Conditions
Healthy
Interventions
Gabapentin 800 mg Tablets, single dose, NEURONTIN® 800 mg Tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 23, 2026, 3:38 PM EDT
Completed Phase 4 Interventional Results available

Fenofibrate in Type 2 Diabetes

NCT03829514
View directory record Official record
Conditions
Diabetes Mellitus, Type II
Interventions
Fenofibrate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 23, 2026, 3:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia

NCT01088984
View directory record Official record
Conditions
Leukemia
Interventions
Bendamustine
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
1 Year to 20 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Orange, California • San Diego, California • St. Petersburg, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Oct 23, 2026, 3:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma

NCT00916058
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bendamustine, Melphalan
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 23, 2026, 3:38 PM EDT
No Longer Available No phase listed Expanded access

Compassionate Use Re-Infusion of ATLCAR.CD30

NCT03914885
View directory record Official record
Conditions
Hodgkin Lymphoma, Adult
Interventions
ATLCAR.CD30, Bendamustine, Fludarabine
Genetic · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 23, 2026, 3:38 PM EDT
Completed Phase 2 Interventional Results available

Gabapentin Treatment of Cannabis Dependence

NCT00974376
View directory record Official record
Conditions
Cannabis Dependence, Cannabis Withdrawal, Cognitive Deficits
Interventions
gabapentin 1200mg/day, Placebo, Manual-guided behavioral counseling
Drug · Behavioral
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Oct 23, 2026, 3:38 PM EDT
Recruiting Phase 2 Interventional

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT04606914
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer
Interventions
mirvetuximab soravtansine (MIRV; IMGN853)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 23, 2026, 3:38 PM EDT
Completed Phase 4 Interventional Results available

Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate

NCT04006925
View directory record Official record
Conditions
REM Sleep Behavior Disorder, Parkinson Disease
Interventions
Sodium Oxybate, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
40 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 23, 2026, 3:38 PM EDT
Completed Phase 2 Interventional Results available

VIGABatrin in Post-anoxic STATus Epilepticus - Phase IIa

NCT04772547
View directory record Official record
Conditions
Status Epilepticus, Electrographic, Coma
Interventions
Vigabatrin Only Product
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 23, 2026, 3:38 PM EDT
Terminated Phase 2 Interventional Results available

Baclofen Effects on Smoking Urge and Withdrawal

NCT00257894
View directory record Official record
Conditions
Nicotine Use Disorder, Nicotine Dependence, Smoking, Tobacco Use Disorder
Interventions
Baclofen, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 23, 2026, 3:38 PM EDT
Withdrawn Phase 2 Interventional

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

NCT01131247
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
ofatumumab + bendamustine
Drug
Lead sponsor
Nevada Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
PHoenix/Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 23, 2026, 3:38 PM EDT
Withdrawn Phase 3 Interventional

Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study

NCT02219373
View directory record Official record
Conditions
Pediatric Chronic Neuropathic Pain
Interventions
Gabapentin, Oxcarbazepine, Placebo
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 3:38 PM EDT
Recruiting Phase 3 Interventional

Emergency Department-Initiated Medications for Alcohol Use Disorder

NCT05827159
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Naltrexone Pill, Naltrexone Injection, Brief Negotiation Interview, Gabapentin Pill
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 23, 2026, 3:38 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms

NCT03421496
View directory record Official record
Conditions
Infantile Spasm
Interventions
Cannabidiol Oral Solution, Placebo, Vigabatrin
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
1 Month to 24 Months
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Miami, Florida • Royal Oak, Michigan • Akron, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 23, 2026, 3:38 PM EDT
Completed Phase 2 Interventional Results available

FEnofibRate as a Metabolic INtervention for COVID-19

NCT04517396
View directory record Official record
Conditions
Covid19
Interventions
Fenofibrate/fenofibric acid, Placebo, Usual care
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 23, 2026, 3:38 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Gabapentin Treatment of Benzodiazepine Dependence

NCT01893632
View directory record Official record
Conditions
Benzodiazepine Dependence
Interventions
gabapentin, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 23, 2026, 3:38 PM EDT
Completed Phase 2 Interventional Results available

Gabapentin for Bipolar & Cannabis Use Disorders

NCT03334721
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder, Cannabis Use Disorder, Substance Use Disorders
Interventions
Gabapentin, Placebo Oral Capsule
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 23, 2026, 3:38 PM EDT